A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).

Rana R Mckay,Roberto Pili,Tyler M Seibert,Deaglan Joseph Mchugh,Jennifer Gomez,Aditya Bagrodia,Karie Runcie,Archana Ajmera,Arlene Araneta,Christopher J Kane,Huihui Ye,Juan Javier-Desloges,Lin Liu,Kenneth Offit,Kit L Yuen,Neremiah Castano,Naomi B Haas,Channing Judith Paller,Minya Pu

doi:10.1200/jco.2024.42.16_suppl.tps5128

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).

Rana R Mckay, Roberto Pili + Show 17 more

https://doi.org/10.1200/jco.2024.42.16_suppl.tps5128

Copy DOI

Export

Save

Cite

Journal: Journal of Clinical Oncology

Publication Date: Jun 1, 2024

#Unfavorable Intermediate-risk #High-risk Prostate Cancer #Unfavorable Intermediate-risk Prostate Cancer #Radical Prostatectomy #Gene Alterations #Intermediate-risk Prostate Cancer #Study Of Inhibition #PARP Inhibition #Prostate Cancer

Abstract
Full-Text
Similar Papers

Abstract

Listen

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with <i>BRCA1/2</i> gene alterations (NePtune).

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).